Market Research Report
Bespoke Cancer Treatment Using Vaccines: Exploring the Possibility of Changing the Treatment Paradigm
|Published by||DelveInsight Business Research LLP||Product code||924081|
Delivery time: 1-2 business days
|Bespoke Cancer Treatment Using Vaccines: Exploring the Possibility of Changing the Treatment Paradigm|
|Published: March 4, 2020||Content info:||
Despite of the expanding oncology pipeline, cancer vaccines contribute only to a minor share of total oncology-attributed revenues owing to the limited number of approved products. Although, the FDA approved a personalized vaccine Sipuleucel-T (Provenge) for men with metastatic prostate cancer in 2010. Cancer vaccine development is well known for its high development costs and risks, low historical rates of investment return, high probability of failures arising in ventures, partnerships and alliances. The cost of reimbursement for novel oncology therapies is not universally acceptable to payers limiting the potential for a global expansion, market access and reducing probability of commercial success.
However, a positive light can be thrown on the upcoming cancer therapeutic vaccines, which boosts the immune system's ability to recognize and destroy antigens. The current research and development is focussed more on developing personalized vaccines. These types of vaccines are produced from the person's tumor sample. Other cancer vaccines target specific cancer antigens and are given to people whose tumors have those antigens on the surface of the tumor cells. The major vaccine types in development are peptide vaccines, dendritic cell vaccines, mRNA and DNA based vaccines and neo-antigen vaccines through novel technology platforms.
The upcoming market of cancer vaccines is blooming with promising therapeutic vaccine. In terms of the cancer indications, the most benefitted one's with respect to a good number of upcoming vaccines by major key players are prostate cancer (Advantagene), NSCLC (OSE immunotherapuetics), pancreatic cancer (Nantkwest), melanoma, followed by DLBCL, Breast cancer and colorectal cancers. Other cancers such as Bladder cancer, Glioblastoma's, Microsatellite Instability-High Cancers, Anal and Rectal cancers are also under the light of development with equally potential therapeutic vaccines.
Highlighting the major key players' along with their potential developments in trial, such as Advantagene's Prostatak and OSE immunotherapeutics' Tedopi will be the first to market position due to their early launches in the United States, EU5 Countries followed by Japan. While other potential players are Moderna and Neon Therapeutics.
Out of the 20+ promising therapeutic cancer vaccines ((there are 100+ in total), including 14+ indications in high stages of development most of them are targeting recurrent and advanced stages of cancer, except the one being developed for first line treatment of patients with Glioblastoma Multiforme.
Another major key players are Nantkwest and Immunovaccine technologies, in terms of targeting the maximum number of cancer indications. Nantkwest's hank vaccine is being evaluated in combination with avelumab for Triple Negative Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma and Pancreatic Cancer along with few other indications in early stages of testing. While Immunovaccine technologies's DPX-Survivac (Survivin) is being developed in combination with Keytruda for Ovarian cancer, DLBCL, NSCLC, bladder, HCC, melanoma along with few other cancers.
These budding vaccines are majorly tested in combination with radiation therapy, chemotherapy, adjuvants with either their respective standard of care (SOC) therapies or I-O therapies involving PD-1/PD-L1 such as pemrolizumab, nivolumab etc. It's mesmerizing that not just the upcoming vaccine market is expected to boom in the coming years, but along it will also strengthen the already existing market of blockbuster PD-1/PD-L1 inhibitors, fulfilling the best choice for adjuvants.
In conclusion, therapeutic cancer vaccines have the potential to address several unmet needs that persist in cancer treatment paradigm currently. It's likely that they will prove their value as high efficacy, promising and low-toxicity treatment options for early-stage disease and by enhancing the efficacy of existing regimens in late-stage disease.
In this report we have captured the commercial potential of all potential cancer treatment vaccine targeting multiple indications in next 10-15 years.